THỜI GIAN SỐNG CÒN TOÀN BỘ VÀ MỘT SỐ YẾU TỐ TIÊN LƯỢNG CỦA BỆNH NHÂN UNG THƯ HẮC TỐ DA GIAI ĐOẠN CHƯA DI CĂN XA

Abstract

Objectives: To evaluate overall survival time and some prognostic factors of patients with stage I, II, and III melanoma. Subjects and research methods: A cross-sectional descriptive study on cutaneous melanoma patients with stage I, II, and III skin cancer treated at Vietnam National Cancer Hospital from January 2018 to December 2021. Kaplan-Meier curves were used to estimate time overall survival (OS). The impact of baseline characteristics on OS was explored using multivariate Cox proportional hazard models. Results: 72,6% of patients received wide tumor resection and lymph node dissection, 25,0% had amputation/arthroplasty and lymph node dissection, and 2,4% of patients only received wide tumor resection or amputation. simple limb/disarticulation. 54,8% of patients did not have indications for adjuvant treatment after surgery (these patients were all in stages I and II), 10,7% of patients refused adjuvant treatment, and 22,6% of patients received treatment adjuvant chemotherapy, 11,9% of patients received adjuvant treatment with the immunotherapy drug pembrolizumab. The median overall survival time was 35,9 months, (95%CI is 28,7-43,1 months). Patients with tumor thickness T1-2, disease stage I-II, no tumor ulceration, no vascular invasion, no lymphocytic infiltration, and a mitotic ratio ≤ 6 have a higher overall survival time (p < 0,05). Among them, disease stage I-II and no vascular invasion are two factors that have independent prognostic value for overall survival. Conclusion: For patients with non-metastatic stage melanoma, surgery is the most important treatment method. The median overall survival time was 35,9 months, (95%CI is 28,7-43,1 months). Of which, disease stage I-II and no vascular invasion are two factors